Who
Matthew Link
Director
Company insider
Files Form 4 as: Director, FibroBiologics; Chief Commercial Officer, Sight Sciences; President, Nuvasive.
In numbers
- Trades disclosed
- 138
- Buys
- 0
- Sells
- 20
- Bought
- $0
- Sold
- $4.0M
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 1 Jan 2013
- Last trade
- 23 Jun 2026
- Last filed
- 23 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 23 Jun 2026filed 23 Jun 2026 | FBLG FibroBiologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,803 at $0.00 | filing |
| 23 Jun 2026filed 23 Jun 2026 | FBLG FibroBiologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,803 at $0.00 | filing |
| 2 Jul 2025filed 7 Jul 2025 | SGHT Sight SciencesMedical Devices | SEC FORM 4 Sold | $20K4,889 at $4.10 | filing |
| 12 Jun 2025filed 12 Jun 2025 | FBLG FibroBiologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
| 16 May 2025filed 21 May 2025 | SGHT Sight SciencesMedical Devices | SEC FORM 4 Code A | $20K6,631 at $3.02 | filing |
| 2 Apr 2025filed 3 Apr 2025 | SGHT Sight SciencesMedical Devices | SEC FORM 4 Sold | $12K5,042 at $2.31 | filing |
| 11 Mar 2025filed 13 Mar 2025 | SGHT Sight SciencesMedical Devices | SEC FORM 4 Code A | —172,043 at $0.00 | filing |
| 21 Oct 2024filed 21 Oct 2024 | SGHT Sight SciencesMedical Devices | SEC FORM 4 Sold | $122K21,831 at $5.61 | filing |
| 18 Oct 2024filed 21 Oct 2024 | SGHT Sight SciencesMedical Devices | SEC FORM 4 Sold | $123K20,487 at $5.98 | filing |
| 17 Oct 2024filed 18 Oct 2024 | SGHT Sight SciencesMedical Devices | SEC FORM 4 Sold | $122K20,970 at $5.84 | filing |
| 16 Oct 2024filed 18 Oct 2024 | SGHT Sight SciencesMedical Devices | SEC FORM 4 Sold | $123K20,734 at $5.91 | filing |
| 27 Aug 2024filed 27 Aug 2024 | FBLG FibroBiologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,000 at $0.00 | filing |
| 14 Nov 2023filed 16 Nov 2023 | SGHT Sight Sciencesoption or derivative · Medical Devices | SEC FORM 4 Code A | —526,430 at $0.00 | filing |
| 14 Nov 2023filed 16 Nov 2023 | SGHT Sight SciencesMedical Devices | SEC FORM 4 Code A | —747,572 at $0.00 | filing |
| 8 Jun 2020filed 10 Jun 2020 | Nuvasive | SEC FORM 4 Sold | $201K3,000 at $67.00 | filing |
| 2 Mar 2020filed 3 Mar 2020 | Nuvasiveoption or derivative | SEC FORM 4 Code A | —12,190 at $0.00 | filing |
| 1 Mar 2020filed 3 Mar 2020 | Nuvasiveoption or derivative | SEC FORM 4 Code M | —7,929 at $0.00 | filing |
| 1 Mar 2020filed 3 Mar 2020 | Nuvasive | SEC FORM 4 Code M | —7,929 at $0.00 | filing |
| 1 Mar 2020filed 3 Mar 2020 | Nuvasive | SEC FORM 4 Code F | $182K2,769 at $65.81 | filing |
| 16 Jan 2020filed 17 Jan 2020 | Nuvasive | SEC FORM 4 Sold | $239K3,000 at $79.80 | filing |
News
No headline names them, or the companies they trade most, lately.